J. M. Ferrero-Cafiero

Impact of Chiral Bioanalytical Methods on the Bioequivalence of Ibuprofen Products Containing Ibuprofen Lysinate and Ibuprofen Base.

R. Antonijoan, M. Puntes, I. Gich, 2016, Chirality.

SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer.

M. Juan, E. Zamora, A. Prat, 2020, Future oncology.

First-in-Human Randomized Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the KDM1A Inhibitor Vafidemstat

C. Buesa, R. Antonijoan, M. Puntes, 2021, CNS Drugs.

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer

A. Prat, P. Villagrasa, B. González-Farré, 2021, Frontiers in Oncology.

FIRST-IN-HUMAN PHASE I RESULTS SHOW SAFETY, TOLERABILITY AND BRAIN PENETRANCE OF ORY-2001, AN EPIGENETIC DRUG TARGETING LSD1 AND MAO-B

R. Antonijoan, T. Maes, J. M. Ferrero-Cafiero, 2017, Alzheimer's & Dementia.

124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trial

A. Prat, J. M. Ferrero-Cafiero, T. Pascual, 2023, ESMO Open.

Patritumab Deruxtecan in Untreated Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Final Results from Part A of the Window-of-Opportunity SOLTI TOT-HER3 Pre-Operative Study.

B. González-Farré, D. Sellami, J. M. Ferrero-Cafiero, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

155TiP A randomised phase II trial of neoadjuvant multi-agent chemotherapy (CHT) OR patritumab deruxtecan (HER3-DXd; U3-1402) +/- endocrine therapy (ET) for high-risk hormone receptor-positive (HR+/HER2-) early breast cancer (EBC): SOLTI-2103 VALENTINE trial

A. Prat, J. M. Ferrero-Cafiero, T. Pascual, 2023, ESMO Open.